<![CDATA[ONCOLOGY VENTURE- Q&A D.6/11-2019 - TRANSCRIPT]]>Transcript pĂĄ dagens Q&A med CFO Henrik Moltke.

78880_QA_Oncology_Venture_2019_11_06.pdf

]]>https://dev.proinvestor.com/forum/topic/440493/oncology-venture-qa-d611-2019-transcriptRSS for NodeTue, 14 Jul 2026 12:34:53 GMTWed, 06 Nov 2019 20:52:45 GMT60<![CDATA[Reply to ONCOLOGY VENTURE- Q&A D.6/11-2019 - TRANSCRIPT on Wed, 13 Nov 2019 09:09:41 GMT]]>Interessant interview

Attention Required! | Cloudflare

favicon

(www.biostock.se)

]]>https://dev.proinvestor.com/forum/post/9455490https://dev.proinvestor.com/forum/post/9455490Wed, 13 Nov 2019 09:09:41 GMT<![CDATA[Reply to ONCOLOGY VENTURE- Q&A D.6/11-2019 - TRANSCRIPT on Tue, 12 Nov 2019 13:40:34 GMT]]>Gode takter i dag fra OV 🙂

Et par overskrifter fra dagens PM:

Oncology Venture A/S: Oncology Venture reaches new development milestone with Dovitinib.

og

Oncology Venture A/S: Oncology Venture advancing towards next milestone in its clinical development of 2X-121

Er ikke selv inde i det teknologiske men idéen med at præcicere hvilken medicin der virker på hvilke kræftpatienter virker meget interessant.

]]>https://dev.proinvestor.com/forum/post/9455489https://dev.proinvestor.com/forum/post/9455489Tue, 12 Nov 2019 13:40:34 GMT